AbbVie (ABBV) Intangibles (2012 - 2026)
AbbVie (ABBV) posted quarterly Intangibles of $50.9 billion for Q1 2026, down 13.02% year-over-year from $58.5 billion in Q1 2025, and down 3.36% quarter-over-quarter from $52.6 billion in Q4 2025.
AbbVie (ABBV) Intangibles (2012 - 2026) Analysis & Trends
AbbVie (ABBV) has reported Intangibles for 15 consecutive years, with $50.9 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Intangibles fell 13.02% year-over-year to $50.9 billion; the TTM figure through Mar 2026 stood at $50.9 billion (down 13.02% YoY), while the FY2025 annual figure was $52.6 billion, down 12.36% from the prior year.
- Intangibles slipped to $50.9 billion in Q1 2026 per ABBV's latest filing, from $52.6 billion in the prior quarter.
- Across five years, Intangibles topped out at $74.0 billion in Q1 2022 and bottomed at $711.0 million in Q3 2025.
- Historically, Intangibles has averaged $58.4 billion across 5 years, with a median of $60.2 billion in 2024.
- Annual changes were most pronounced in 2024 — Intangibles grew 13.72% — and 2025, when it plunged 98.93%.
- AbbVie's Intangibles stood at $67.4 billion in 2022, then declined by 17.54% to $55.6 billion in 2023, then increased by 8.02% to $60.1 billion in 2024, then dropped by 12.36% to $52.6 billion in 2025, then retreated by 3.36% to $50.9 billion in 2026.
- Business Quant data shows ABBV's Intangibles at $50.9 billion in Q1 2026, $52.6 billion in Q4 2025, and $711.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.03 Bn | 631.27 Bn | 17.26 Bn | 48.23 Bn |
| 2 | AbbVie | 469.49 Bn | 462.92 Bn | 12.70 Bn | 49.14 Bn |
| 3 | Merck | 375.14 Bn | 368.00 Bn | 12.21 Bn | 24.98 Bn |
| 4 | Novartis Ag | 302.92 Bn | 295.23 Bn | 11.24 Bn | 42.07 Bn |
| 5 | Astrazeneca | 257.73 Bn | 252.83 Bn | 12.86 Bn | 37.72 Bn |
| 6 | Amgen | 236.80 Bn | 222.81 Bn | 7.24 Bn | 20.49 Bn |
| 7 | Gilead Sciences | 182.42 Bn | 179.24 Bn | 6.22 Bn | 14.03 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 47.05 Bn |
| 9 | Gsk | 106.16 Bn | 101.99 Bn | 8.24 Bn | 22.54 Bn |
| 10 | Sanofi | 55.18 Bn | 47.80 Bn | 10.79 Bn | 30.64 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 49.14 Bn |
| Mar 31, 2026 | 50.87 Bn |
| Dec 31, 2025 | 52.64 Bn |
| Sep 30, 2025 | 711.00 Mn |
| Jun 30, 2025 | 57.03 Bn |
| Mar 31, 2025 | 58.49 Bn |
| Dec 31, 2024 | 60.07 Bn |
| Sep 30, 2024 | 66.65 Bn |
| Jun 30, 2024 | 60.24 Bn |
| Mar 31, 2024 | 62.23 Bn |
| Dec 31, 2023 | 55.61 Bn |
| Sep 30, 2023 | 58.60 Bn |
| Jun 30, 2023 | 62.86 Bn |
| Mar 31, 2023 | 64.85 Bn |
| Dec 31, 2022 | 67.44 Bn |
| Sep 30, 2022 | 68.73 Bn |
| Jun 30, 2022 | 71.82 Bn |
| Mar 31, 2022 | 73.99 Bn |
| Dec 31, 2021 | 75.95 Bn |
| Sep 30, 2021 | 77.46 Bn |